ACGSD - Celgene Acquisition of Receptos Inc for 7.8 Billion

Share:
ACG EVENT

Event Details

When:

February 16, 2016 5 AM - 7 AM PST

Add to Calendar

Overview

Body
Celgene Acquisition of Receptos, Inc. for 7.8 Billion

Tuesday February 16, 2016 / 7 - 9 am / Lomas Santa Fe Country Club
1505 Lomas Santa Fe Dr, Solana Beach, CA 92075



How do you build a 7 billion dollar company and guide it through sale in 7 years?  Join us as we speak with Faheem Hasnain, President and CEO of San Diego biotech Receptos until its recent sale in August 2015.  Faheem has the distinction of having run and transitioned several successful biotech companies.  How did he build his team? What can we learn from his deal-making experiences?  Bring your questions as he generously shares his insights with us on February16, 2016. ACG “Where Dealmakers Meet.” 
 
 
PANEL: 
 
Faheem Hasnain, President and CEO of San Diego biotech Receptos 
Receptos was a public company formed in 2009 with specific focus in immunology and metabolic disorders and was purchased by Celgene Corporation for 7.8 Billion in August 2015. Prior to joining Receptos, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation from December 2008 until the company’s acquisition by Abbott Laboratories in April 2010. Mr. Hasnain was President, Chief Executive Officer and a director of PDL BioPharma, Inc. from October 2008 until Facet Biotech was spun off from PDL BioPharma in December 2008. From October 2004 to September 2008, Mr. Hasnain served at Biogen Idec Inc., most recently as Executive Vice President in charge of the oncology/rheumatology strategic business unit.

Carol Gallagher, Partner, New Enterprise Associates- Moderator
Carol Gallagher joined New Enterprise Associates (NEA) in October 2014, where she is primarily focused on biopharma investments. Carol is a proven entrepreneur, operator and more recently investor with more than 25 years of experience in commercial, drug development and business development roles. Prior to joining NEA, she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards including Aragon Pharmaceuticals. From 2008-2011, Dr. Gallagher was the president and CEO of Calistoga Pharmaceuticals that developed the first cancer therapeutic ZYDELIG. During her tenure as CEO at Calistoga, Dr. Gallagher raised 80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for 375 million and a total consideration of 600 million.


SPONSORS:

CohnReznick
 
Northern Trust
 
Vantage Point 


REGISTRATION OPEN NOW

ACG Annual Sponsors & Members with Breakfast Meetings Included : 0
ACG Members Pay as You Attend & Other Chapters: 65
Non-Members & Guests: 85

LATE Registration (effective Feb 13) Save 10 if you register by Feb 12!!

ACG Annual Sponsors & Members with Breakfast Meetings Included : 0
ACG Members Pay as You Attend & Other Chapters: 75
Non-Members & Guests: 95


Questions: Contact Executive Director Judy Susser-Travis, CMP, CMM
at acgsandiego@acg.org or call 619-741-7247 for assistance.
 
 
Hosted by: ACG
Chapter
San Diego
Share: